SCHEMBL6263283

SCHEMBL6263283

COC(=O)CCC(=O)Nc1cccc2c1C(=O)C(=O)c1ccccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 6/20 1.00
PTPN13 Q12923 3/20 1.00
ALDH1A1 P00352 2/20 0.61
POLB P06746 2/20 0.61
CYP1A2 P05177 1/20 0.59
CYP2C19 P33261 1/20 0.59
TERT O14746 8/20 0.56
CTSL P07711 1/20 0.56
MAPT P10636 2/20 0.54
MEN1 O00255 1/20 0.54
GAA P10253 1/20 0.54
DNMT1 P26358 1/20 0.54
RAD52 P43351 1/20 0.54
SMARCA2 P51531 1/20 0.54
KMT2A Q03164 1/20 0.54
MAOA P21397 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6258519 0.92 PTPRC (0.85) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6264027 0.84 PTPRC (0.73) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6259066 0.83 PTPRC (0.71) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6263526 0.83 PTPRC (0.71) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6261141 0.80 PTPRC (0.73) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6261316 0.78 PTPRC (1.00) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL6260674 0.78 PTPRC (0.95) PTPRCPTPN13ALDH1A1POLBCYP1A2
SCHEMBL11656337 0.78 MAOA (0.64) PTPRCPTPN13ALDH1A1POLBTERT
SCHEMBL14240479 0.76 PTPRC (0.62) PTPRCPTPN13ALDH1A1POLBTERT
SCHEMBL14240481 0.76 PTPRC (0.62) PTPRCPTPN13ALDH1A1POLBTERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242363-B1 CD45 INHIBITORS ASTRAZENECA AB (SE) 2005-11-02 EP disclosed
US-20030207812-A1 Cd45 inhibitors ASTRAZENECA AB (SE) 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207812-A1 Cd45 inhibitors CD74, CD2, PTPRC PTPRC 3/4885PTPN13 69/4885ALDH1A1 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.